HR Execs on the Move

Tetraphase

www.tphase.com

 
Tetraphase Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing novel antibiotics to treat the serious and life-threatening multidrug-resistant infections that pose a major and growing global health threat. Tetraphase`s proprietary breakthrough chemistry technology enables the design of molecules that can overcome antibiotic resistance. Our drug platform has led to the creation of more than 3,000 broad- and selective-spectrum antibiotic drug candidates. Tetraphase common stock trades under the NASDAQ symbol `TTPH.` Tetraphase is well positioned to be a major player in the multidrug-resistant arena.
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million
  • www.tphase.com
  • 480 Arsenal Street Suite 110
    Watertown, MA USA 02472
  • Phone: 617.715.3600

Executives

Name Title Contact Details

Similar Companies

Deltanoid Pharmaceuticals

Deltanoid Pharmaceuticals is a Madison, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Tapimmune Inc

Tapimmune Inc is a Issaquah, WA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Cingulate

The Investor Relations website contains information about Cingulate Incs business for stockholders, potential investors, and financial analysts.

Enanta

Enanta Pharmaceuticals is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs for the treatment of viral infections. Two protease inhibitors, glecaprevir and paritaprevir, discovered and developed through Enanta`s collaboration with AbbVie, have now been approved around the world as part of AbbVie`s regimens for the treatment of hepatitis C virus (HCV) infection. The leading regimen is sold under the tradenames MAVYRET™ (U.S.) and MAVIRET™ (ex-U.S.) (glecaprevir/pibrentasvir). Royalties from the AbbVie collaboration are helping to fund Enanta`s research and development efforts, which are currently focused on the following disease targets: respiratory syncytial virus (RSV), hepatitis B virus (HBV), SARS-CoV-2 (COVID-19) and human metapneumovirus (hMPV).

Reistone Biopharma